Advertisement

Risk of unexpected uterine Cancer in women undergoing myomectomy: A population-based study

      Up to 70% of American women develop uterine fibroids (benign smooth muscle tumors) by age 49 [
      • Hartmann K.E.
      • Fonnesbeck C.
      • Surawicz T.
      • Krishnaswami S.
      • Andrews J.C.
      • Wilson J.E.
      • et al.
      Management of uterine fibroids. Comparative Effectiveness Review No. 195.
      ]. Myomectomy, surgical removal of fibroids while preserving the uterus, offers a treatment option for women who desire future fertility [
      • Hartmann K.E.
      • Fonnesbeck C.
      • Surawicz T.
      • Krishnaswami S.
      • Andrews J.C.
      • Wilson J.E.
      • et al.
      Management of uterine fibroids. Comparative Effectiveness Review No. 195.
      ]. Although a common gynecologic procedure, myomectomy is not appropriate for patients with suspected or known cancer. Yet fibroids may present with similar symptoms as uterine sarcomas, and there is heightened concern about unrecognized uterine cancer since the U.S. Food and Drug Administration issued safety warnings against power morcellation of uterine tissues [
      • U.S. Food and Drug Administration
      FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids.
      ]. However, data on the risk of unexpected uterine cancer specifically for women undergoing myomectomy are limited, as prior research has centered on hysterectomies (surgical removal of the uterus). We addressed this important gap using a large population-based sample.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Hartmann K.E.
        • Fonnesbeck C.
        • Surawicz T.
        • Krishnaswami S.
        • Andrews J.C.
        • Wilson J.E.
        • et al.
        Management of uterine fibroids. Comparative Effectiveness Review No. 195.
        Agency for Healthcare Research and Quality, Rockville, MD2017https://doi.org/10.23970/AHRQEPCCER195 (AHRQ Publication No. 17(18)-EHC028-EF. https://effectivehealthcare.ahrq.gov/topics/uterine-fibroids/research-2017)
        • U.S. Food and Drug Administration
        FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids.
        Silver Spring, MD2017 (Available at: https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupport/UCM584539.pdf. Accessed August 14, 2018)
        • Bean E.M.
        • Cutner A.
        • Holland T.
        • Vashisht A.
        • Jurkovic D.
        • Saridogan E.
        Laparoscopic myomectomy: A single-center retrospective review of 514 patients.
        J Minim Invasive Gynecol. 2017; 24: 485-493
        • Brohl A.S.
        • Li L.
        • Andikyan V.
        • Običan S.G.
        • Cioffi A.
        • Hao K.
        • et al.
        Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.
        Oncologist. 2015; 20: 433-439
        • Sizzi O.
        • Manganaro L.
        • Rossetti A.
        • Saldari M.
        • Florio G.
        • Loddo A.
        • et al.
        Assessing the risk of laparoscopic morcellation of occult uterine sarcomas during hysterectomy and myomectomy: Literature review and the ISGE recommendations.
        Eur J Obstet Gynecol Reprod Biol. 2018; 220: 30-38